Global law firm Goodwin Procter has been enlisted by GSK for its $1.15 billion acquisition of a U.S. biopharmaceutical business specializing in cancer treatment. The deal announcement was made public on the London Stock Exchange, marking another significant move in GSK’s strategic expansion in the oncology sector.
For further details on the acquisition, the original announcement can be accessed through the source article. Please note that the article might be paywalled, but the link provides some additional context.